mk-8237

Showing 1 posts of 1 posts found.

msd

FDA accepts biologics license application for MSD’s allergy immunotherapy drug

April 13, 2016
Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …

Latest content